Press Releases

02.27.2017

Arrakis Therapeutics Announces $38M Series A Financing To Target RNA with Small-Molecule Medicines And Names Michael Gilman Chairman and CEO

02.24.2017

Pfizer Prices $1,065,000,000 Debt Offering

02.23.2017

Ronald E. Blaylock Elected to Pfizer’s Board of Directors

02.22.2017

Startup accelerator BaseLaunch aims to attract promising healthcare ventures to Basel, Europe’s leading life sciences hub.

02.21.2017

Pfizer Announces Acceptance of Regulatory Submission for Inotuzumab Ozogamicin by the U.S. Food and Drug Administration

02.17.2017

New Data in Crohn’s Disease Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA® and REMICADE®a

02.16.2017

Pfizer Announces Top-Line Results from the Oral Strategy Trial of XELJANZ® (tofacitinib citrate) Compared to Humira® (adalimumab)

02.08.2017

Pfizer Receives FDA Approval for EUCRISA™ (crisaborole)

02.08.2017

Relationship Expert Teams Up with Pfizer to Address Intimacy and Relationship Issues for People Living with Chronic Diseases

01.31.2017

Edelris Announces Research Collaboration Agreement with Pfizer Inc.

01.31.2017

PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2016 RESULTS

01.27.2017

Pfizer Receives Positive CHMP Opinion in Europe for XELJANZ® (tofacitinib citrate) for the Treatment of Moderate to Severe Active Rheumatoid Arthritis